Yarely M. Salinas Vera

Dr. Yarely M. Salinas Vera

Universidad Autónoma de la Ciudad de México, Mexico City, Ciudad de México, Mexico
+1
orcid
Post Doctoral Researcher

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2020 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
OCOlga N. Hernández de la Cruz
Olga N. Hernández de la Cruz
JLJosé Sullivan López-González
José Sullivan López-González
RGRaúl García-Vázquez
Raúl García-Vázquez
Yarely M. Salinas VeraYarely M. Salinas Vera
Yarely M. Salinas Vera
MMMarcos A. Muñiz-Lino
Marcos A. Muñiz-Lino
ACAngeles Carlos-Reyes
Angeles Carlos-Reyes
Vasculogenic mimicry (VM) is a mechanism whereby cancer cells form microvascular structures similar to three-dimensional channels to provide nutrients and oxygen to tumors. Unlike angiogenesis, VM is characterized by the development of new patterned three-dimensional vascular-like structures independent of endothelial cells. This phenomenon has been observed in many types of highly aggressive solid tumors. The presence of VM has also been associated with increased resistance to chemotherapy, low survival, and poor prognosis. MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) are non-coding RNAs that regulate gene expression at the post-transcriptional level through different pathways. In recent years, these tiny RNAs have been shown to be expressed aberrantly in different human malignancies, thus contributing to the hallmarks of cancer. In this context, miRNAs and lncRNAs can be excellent biomarkers for diagnosis, prognosis, and the prediction of response to therapy. In this review, we discuss the role that the tumor microenvironment and the epithelial-mesenchymal transition have in VM. We include an overview of the mechanisms of VM with examples of diverse types of tumors. Finally, we describe the regulation networks of lncRNAs-miRNAs and their clinical impact with the VM. Knowing the key genes that regulate and promote the development of VM in tumors with invasive, aggressive, and therapy-resistant phenotypes will facilitate the discovery of novel biomarker therapeutics against cancer as well as tools in the diagnosis and prognosis of patients.

27 November 2018 in International Journal of Molecular Medicine
Verified
Journal Article
Closed access
PDF file
Yarely M. Salinas VeraYarely M. Salinas Vera
Yarely M. Salinas Vera
LMLaurence A Marchat
Laurence A Marchat
HVHoracio Astudillo-De La Vega
Horacio Astudillo-De La Vega
DGDolores Gallardo‑Rincón
Dolores Gallardo‑Rincón
ERErika Ruiz‑García
Erika Ruiz‑García
César López-CamarilloCésar López-Camarillo
César López-Camarillo
Angiogenesis is an important hallmark of cancer serving a key role in tumor growth and metastasis. Therefore, tumor angiogenesis has become an attractive target for development of novel drug therapies. An increased amount of anti-angiogenic compounds is currently in preclinical and clinical development for personalized therapies. However, resistance to current angiogenesis inhibitors is emerging, indicating that there is a need to identify novel anti-angiogenic agents. In the last decade, the field of microRNA biology has exploded revealing unsuspected functions in tumor angiogenesis. These small non-coding RNAs, which have been dubbed as angiomiRs, may target regulatory molecules driving angiogenesis, such as cytokines, metalloproteinases and growth factors, including vascular endothelial growth factor, platelet-derived growth factor, fibroblast growth factor, epidermal growth factor, hypoxia inducible factor-1, as well as mitogen-activated protein kinase, phosphoinositide 3-kinase and transforming growth factor signaling pathways. The present review discusses the current progress towards understanding the functions of miRNAs in tumor angiogenesis regulation in diverse types of human cancer. Furthermore, the potential clinical application of angiomiRs towards anti-angiogenic tumor therapy was explored.

1 September 2018 in Cancer Letters
Verified
Journal Article
Closed access
Yarely M. Salinas VeraYarely M. Salinas Vera
Yarely M. Salinas Vera
LMLaurence A Marchat
Laurence A Marchat
RGRaúl García-Vázquez
Raúl García-Vázquez
Claudia Haydée González De La RosaClaudia Haydée González De La Rosa
Claudia Haydée González De La Rosa
ECEduardo Castañeda-Saucedo
Eduardo Castañeda-Saucedo
César López-CamarilloCésar López-Camarillo
César López-Camarillo

29 November 2019 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
SNStephanie I. Nuñez-Olvera
Stephanie I. Nuñez-Olvera
DGDolores Gallardo-Rincón
Dolores Gallardo-Rincón
Jonathan Puente-RiveraJonathan Puente-Rivera
Jonathan Puente-Rivera
Yarely M. Salinas VeraYarely M. Salinas Vera
Yarely M. Salinas Vera
LMLaurence A Marchat
Laurence A Marchat
César López-CamarilloCésar López-Camarillo
César López-Camarillo
Endometrial cancer is the fourth most frequent neoplasia for women worldwide, and over the past two decades it incidence has increased. The most common histological type of endometrial cancer is endometrioid adenocarcinoma, also known as type 1 endometrial cancer. Endometrioid endometrial cancer is associated with diverse epidemiological risk factors including estrogen use, obesity, diabetes, cigarette smoking, null parity, early menarche, and late menopause. Clinical effectiveness of chemotherapy is variable, indicating that novel molecular therapies against specific cellular processes associated to cell survival and resistance to therapy, such as autophagy, urged to ameliorate the rates of success in endometrial cancer treatment. Autophagy (also known as macroautophagy) is a specialized mechanism that maintains cell homeostasis which is activated in response to cellular stressors including nutrients deprivation, amino acids starvation, hypoxia, and metabolic stress to prolong cell survival via lysosomal degradation of cytoplasmic macromolecules and organelles. However, in human cancer cells, autophagy has a controversial function due to its dual role as self-protective or apoptotic. Conventional antitumor therapies including hormones, chemotherapy and ionizing radiation, may activate autophagy as a pro-survival tumor response contributing to treatment resistance. Intriguingly, if autophagy continues above reversibility of cell viability, autophagy can result in apoptosis of tumor cells. Here, we have reviewed the mechanisms of autophagy described in endometrial cancers, including the role of PI3K/AKT/mTOR, AMPK-mTOR, and p53 signaling pathways that trigger or inhibit the process and thus representing potential molecular targets in therapeutic clinical approaches. In addition, we discussed the recent findings indicating that autophagy can be modulated using repurposing drugs which may leads to faster experimentation and validation, as well as more easy access of the medications to patients. Finally, the promising role of dietary compounds and microRNAs in autophagy modulation is also discussed. In conclusion, although the research about autophagy is scarce but ongoing in endometrial cancer, the actual findings highlight the promising usefulness of novel molecules for directing targeted therapies.

4 April 2017 in International Journal of Oncology
Verified
Journal Article
Closed access
PDF file
CFCarlos Palma Flores
Carlos Palma Flores
RGRaúl García-Vázquez
Raúl García-Vázquez
DRDolores Gallardo Rincón
Dolores Gallardo Rincón
ERErika Ruiz-García
Erika Ruiz-García
HVHoracio Astudillo De La Vega
Horacio Astudillo De La Vega
César López-CamarilloCésar López-Camarillo
César López-Camarillo
Epithelial ovarian cancer is the fifth most frequent cause of cancer death in women. In spite of the advantages in early detection and treatment options, overall survival rates have improved only slightly in the last decades. Therefore, alternative therapeutic approaches need to overcome resistance and improve the patient survival and outcome. MicroRNAs are evolutionary conserved small non-coding RNAs that function as negative regulators of gene expression by inhibiting translation or inducing degradation of messenger RNAs. In cancer, microRNAs are aberrantly expressed thus representing potential prognostic biomarkers and novel therapeutic targets. The knowledge of novel and unexpected functions of microRNAs is rapidly evolving and the advance in the elucidation of potential clinical applications deserves attention. Recently, a specific set of microRNAs dubbed as metastamiRs have been shown to initiate invasion and metastasis in diverse types of cancer. We reviewed the current status of microRNAs in development and progression of ovarian cancer with a special emphasis on tumor cells invasion and metastasis. Also, we show an update of microRNA functions in oncogenic pathways and discuss the current scenario for potential applications in clinical and translational research in ovarian cancer.

26 May 2020 in Non-Coding RNA
Verified
Journal Article
Open access
PDF file
ALAllan Lozano-Romero
Allan Lozano-Romero
HVHoracio Astudillo-De la Vega
Horacio Astudillo-De la Vega
MTMaría Terrones-Gurrola
María Terrones-Gurrola
LMLaurence A Marchat
Laurence A Marchat
DHDaniel Hernández
Daniel Hernández
César López-CamarilloCésar López-Camarillo
César López-Camarillo
HOX transcript antisense RNA (HOTAIR) is an oncogenic long non-coding RNA frequently overexpressed in cancer. HOTAIR can enhance the malignant behavior of tumors by sponging microRNAs with tumor suppressor functions. Vasculogenic mimicry is a hypoxia-activated process in which tumor cells form three-dimensional (3D) channel-like networks, resembling endothelial blood vessels, to obtain nutrients. However, the role of HOTAIR in vasculogenic mimicry and the underlying mechanisms are unknown in human cancers. In the current study, we investigated the relevance of HOTAIR in hypoxia-induced vasculogenic mimicry in metastatic MDA-MB-231 and invasive Hs-578t triple negative breast cancer cells. Analysis of The Cancer Genome Atlas (TCGA) database using cBioPortal confirmed that HOTAIR was upregulated in clinical breast tumors relative to normal mammary tissues. Our quantitative RT-PCR assays showed a significant increase in HOTAIR levels after 48 h hypoxia relative to normoxia in breast cancer cell lines. Remarkably, knockdown of HOTAIR significantly abolished the hypoxia-induced vasculogenic mimicry which was accompanied by a reduction in the number of 3D channel-like networks and branch points. Likewise, HOTAIR silencing leads to reduced cell migration abilities of cancer cells. Bioinformatic analysis predicted that HOTAIR has a potential binding site for tumor suppressor miR-204. Luciferase reporter assays confirmed that HOTAIR is a competitive endogenous sponge of miR-204. Congruently, forced inhibition of HOTAIR in cells resulted in augmented miR-204 levels in breast cancer cells. Further bioinformatic analysis suggested that miR-204 can bind to the 3′ untranslated region of focal adhesion kinase 1 (FAK) transcript involved in cell migration. Western blot and luciferase reporter assays confirmed that FAK is a novel target of miR-204. Finally, silencing of HOTAIR resulted in low levels of cytoplasmic FAK protein and alterations in the organization of cellular cytoskeleton and focal adhesions. In summary, our results showed, for the first time, that HOTAIR mitigates cell migration and vasculogenic mimicry by targeting the miR-204/FAK axis in triple negative breast cancer cells.